WHO ICTRP trial
The study of compairing benefit of Abiraterone low versus full dose with…
CTRI/2023/03/050180 · Clinical Trials Registry India (CTRI) · Recruiting
Key facts
| Trial ID | CTRI/2023/03/050180 |
|---|---|
| Public title | The study of compairing benefit of Abiraterone low versus full dose with Docetaxel in Prostate Cancer |
| Scientific title | DAHLIA: Docetaxel with Abiraterone full versus low dose in Hormone Sensitive Advanced Prostate Cancer â?? Phase III, Non-Inferiority Randomized Control Open Label Trial. - DAHLIA |
| Primary sponsor | Tata Memorial Hospital |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | India |
| Conditions | Health Condition 1: C61- Malignant neoplasm of prostate |
| Interventions | Intervention1: 6 cycles of Docetaxel with Abiraterone 1000mg fasting. : Patient will receive Androgen deprivation therapy (ADT) + Docetaxel chemotherapy with Abiraterone 1000mg in fasting state, followed by continuation of Abiraterone same… |
| Registration date | Jan 3, 2023 |
| Target size | 196 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: